At a glance
At a glance
Cambium Bio Limited (ASX:CMB) is a Sydney-based clinical-stage regenerative medicine company focusing on the development of innovative biologics for ophthalmology and tissue regeneration applications.
Cambium Bio Limited (ASX:CMB) is a Sydney-based clinical-stage regenerative medicine company focusing on the development of innovative biologics for ophthalmology and tissue regeneration applications.
Cambium Bio Limited (ASX:CMB) is a Sydney-based clinical-stage regenerative medicine company focusing on the development of innovative biologics for ophthalmology and tissue regeneration applications.
The Company's proprietary technology, based on human platelet lysate, is being leveraged to create a pipeline of novel therapeutics with a primary focus on ophthalmology.
The Company's proprietary technology, based on human platelet lysate, is being leveraged to create a pipeline of novel therapeutics with a primary focus on ophthalmology.
The Company's proprietary technology, based on human platelet lysate, is being leveraged to create a pipeline of novel therapeutics with a primary focus on ophthalmology.
Cambium Bio's lead product candidate, Elate Ocular®, is being developed to address significant unmet medical needs in the treatment of dry eye disease.
Cambium Bio's lead product candidate, Elate Ocular®, is being developed to address significant unmet medical needs in the treatment of dry eye disease.
Cambium Bio's lead product candidate, Elate Ocular®, is being developed to address significant unmet medical needs in the treatment of dry eye disease.
In addition, the Company's stem cell platform, Progenza™, is being applied to the development of therapies for knee osteoarthritis and other tissue regeneration indications.
In addition, the Company's stem cell platform, Progenza™, is being applied to the development of therapies for knee osteoarthritis and other tissue regeneration indications.
In addition, the Company's stem cell platform, Progenza™, is being applied to the development of therapies for knee osteoarthritis and other tissue regeneration indications.
Cambium Bio is committed to advancing its pipeline through clinical development and commercialization, with the goal of providing transformative treatments to improve patient outcomes.
Cambium Bio is committed to advancing its pipeline through clinical development and commercialization, with the goal of providing transformative treatments to improve patient outcomes.
Cambium Bio is committed to advancing its pipeline through clinical development and commercialization, with the goal of providing transformative treatments to improve patient outcomes.
Board of Directors & Management
Board of Directors & Management
Karolis Rosickas, MS, MBA
Chief Executive Officer
Karolis Rosickas, MS, MBA
Chief Executive Officer
Karolis Rosickas, MS, MBA
Chief Executive Officer
Dr Neera Jagirdar, MD, MPH
Director of Clinical Development
Dr Neera Jagirdar, MD, MPH
Director of Clinical Development
Dr Neera Jagirdar, MD, MPH
Director of Clinical Development
Dr Edmund K. Waller, MD, PhD
Executive Director
Dr Edmund K. Waller, MD, PhD
Executive Director
Dr Edmund K. Waller, MD, PhD
Executive Director
Dr Sebastian Tseng, DDS, MBA
Non-Executive Director
Dr Sebastian Tseng, DDS, MBA
Non-Executive Director
Dr Sebastian Tseng, DDS, MBA
Non-Executive Director
Terence A. Walts, MBA
Executive Director
Terence A. Walts, MBA
Executive Director
Terence A. Walts, MBA
Executive Director
Barry Sechos
Non-Executive Chairman
Barry Sechos
Non-Executive Chairman
Barry Sechos
Non-Executive Chairman
Advisory Board
Advisory Board
Doyle Stulting, MD, PhD
Ophthalmology medical monitor
Doyle Stulting, MD, PhD
Ophthalmology medical monitor
Doyle Stulting, MD, PhD
Ophthalmology medical monitor
Barbara Fant, PharmD
Ophthalmology Regulatory Consultant
Barbara Fant, PharmD
Ophthalmology Regulatory Consultant
Barbara Fant, PharmD
Ophthalmology Regulatory Consultant
Gary R. Stevens, PhD
Clinical statistics consultant
Gary R. Stevens, PhD
Clinical statistics consultant
Gary R. Stevens, PhD
Clinical statistics consultant
Corporate Governance
Corporate governance policies and charters. Cambium Bio and its Board are committed to upholding the highest standards of corporate governance in line with the ASX Corporate Governance Principles and Recommendations (3rd edition).
Careers
Careers
Join a world-class team that is passionate about developing transformational regenerative medicines to treat serious diseases.
Join a world-class team that is passionate about developing transformational regenerative medicines to treat serious diseases.
Corporate Headquarters
Cambium Bio Limited
Address
16 Goodhope Street
Paddington, NSW 2021
Australia
Corporate Headquarters
Cambium Bio Limited
Address
16 Goodhope Street
Paddington, NSW 2021
Australia
Corporate Headquarters
Cambium Bio Limited
Address
16 Goodhope Street
Paddington, NSW 2021
Australia